GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » Market Cap

Tibet Aim Pharm (SZSE:002826) Market Cap : ¥2,435.0 Mil (As of Dec. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Tibet Aim Pharm's share price for the quarter that ended in Sep. 2024 was ¥9.17. Tibet Aim Pharm's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 190.7 Mil. Therefore, Tibet Aim Pharm's market cap for the quarter that ended in Sep. 2024 was ¥1,748.5 Mil.

Tibet Aim Pharm's quarterly market cap declined from Mar. 2024 (¥1,649.4 Mil) to Jun. 2024 (¥1,512.1 Mil) but then increased from Jun. 2024 (¥1,512.1 Mil) to Sep. 2024 (¥1,748.5 Mil).

Tibet Aim Pharm's annual market cap increased from Dec. 2020 (¥1,871.7 Mil) to Dec. 2021 (¥2,093.5 Mil) but then declined from Dec. 2021 (¥2,093.5 Mil) to Dec. 2022 (¥1,943.0 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Tibet Aim Pharm's Enterprise Value for Today is ¥2,087.8 Mil.


Tibet Aim Pharm Market Cap Historical Data

The historical data trend for Tibet Aim Pharm's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm Market Cap Chart

Tibet Aim Pharm Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,938.94 1,953.35 1,871.67 2,093.53 1,943.05

Tibet Aim Pharm Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,196.61 2,263.35 1,649.36 1,512.08 1,748.52

Competitive Comparison of Tibet Aim Pharm's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Aim Pharm's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's Market Cap distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's Market Cap falls into.



Tibet Aim Pharm Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Tibet Aim Pharm's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=¥10.19*190.682
=¥1,943.0

Tibet Aim Pharm's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=¥9.17*190.678
=¥1,748.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tibet Aim Pharm  (SZSE:002826) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Tibet Aim Pharm Market Cap Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Aim Pharm Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Executives
Peng Hui Director
Pang Guo Qiang Directors, executives
Li Qian Jin Securities Affairs Representative
Liu Hang Supervisors

Tibet Aim Pharm Headlines

No Headlines